Biotechnology

Essa Pharma

ESSA Pharmaceuticals Holds Special Meeting to Approve Acquisition of XenoTherapeutics

Essa Pharma released FY2025 Q3 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0901 (forecast USD -0.1697)

Essa Pharma released FY2025 9 Months earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -0.426

ESSA Pharmaceuticals Acquired by XenoTherapeutics

ESSA Pharmaceuticals Reports Q1 EPS Loss Narrowing to 14 Cents

Essa Pharma released FY2025 Q2 earnings on May 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1436 (forecast USD -0.1959)

Essa Pharma released FY2025 Semi-Annual earnings on May 8 (EST), actual revenue USD 0, actual EPS USD -0.3358

ESSA Pharmaceuticals Reports Q2 2025 Net Loss of $6.4 Million

ESSA Pharmaceuticals Conducts Strategic Review and Terminates Clinical Trials

Essa Pharma released FY2025 Q1 earnings on February 11 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.1922 USD (forecast -0.1774 USD)

ESSA Pharma Inc. Explores Strategic Options to Enhance Shareholder Value

Essa Pharma released FY2024 Annual Earnings on December 17, 2024 (EST) with actual revenue of 0 and EPS of -0.6446

Essa Pharma released FY2024 Q4 earnings on December 17, 2024 (EST), with actual revenue of 0 and EPS of -0.1432

ESSA Pharmaceuticals Expects a Loss of 19 Cents per Share in Q3 2024 Report

ESSA Pharmaceuticals Releases Updated Clinical Data for MASOFANITEN

Essa Pharma released FY2024 9 Months Earnings on August 5 (EST) with actual revenue of 0 USD and EPS of -0.5014 USD

ESSA Pharma announces innovative treatment plan for prostate cancer

Essa Pharma released FY2024 Q1 earnings on February 13 (EST), actual revenue 0 USD, actual EPS -0.1351 USD (forecast EPS -0.1732 USD)

EKSO Bionics

Antelope Enterprise

Aimei Health Tech

Profusa

Delixy

Urgently

Jyong Biotech

Cemtrex

CID Holdco

ON24

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap